A Trial Evaluating the Pharmacokinetics and Mode of Action of EndoTAG®-1 in Tumor Patients With Hepatic Metastases
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of study CT 4003 is to assess the behavior of EndoTAG®-1 in the body
(making a so-called pharmacokinetic profile). Therefore, the course of the drug in the body
is examined, i.e. the amount and speed of the drug uptake as well as the distribution and the
elimination of the drug is being investigated. Further objectives of the study are to assess
the effect of EndoTAG®-1 on liver metastases concerning size and blood supply measured by
imaging techniques (contrast-enhanced ultrasound and magnetic resonance imaging as well as
duplex sonography) and to assess the effect on blood markers which are indicators for the
destruction and neoplasm of blood vessels (so-called markers of angiogenesis).